55results about How to "Uniform release rate" patented technology

The invention discloses an embedding method for oxytocin based on squid cuttlebone. Firstly, placing squids into a narcotic, and performing anaesthetization; and then embedding an oxytocin low-release agent into the cuttlebone. The method has the beneficial effects that the embedded oxytocin is located in calcareous cuttlebone of the squids, thus the embedded oxytocin has small stimulation effects on the squids, the cuttlebone has a loose and porous structure, and therefore the oxytocin can be easily released into bodies to play roles; and a certain amount of L-medetomidine is added to R-medetomidine, thus the prepared narcotic has long anaesthetization hold time and a certain analgesic effect, the stress reaction of the squids to an embedding process is greatly reduced, and ink spraying is avoided; and the GnRH low-release agent prepared by using chitosan quaternary ammonium salt as a carrier has good biocompatibility, long release time and a uniform release speed.

The invention relates to drugs for treating mouth mucosa diseases and the manufacture field of the drugs for treating mouth mucosa diseases, in particular to a mouth mucosa drug sustained release preparation for treating a mouth periodontal disease by doxycycline. The preparation is composed of a mouth mucosa contacted layer and a non-adhesiveness sealing layer. The mouth mucosa contacted layer comprises, by weight, 2-20 / 80-98 of antibiotic drugs and auxiliary materials. The components of the non-adhesiveness sealing layer are non-adhesiveness low water-solubility high-molecular polymers. The non-adhesiveness low water-solubility high-molecular polymers are chosen from polyvinyl alcohol. The components of mouth mucosa drug sustained release preparation comprise 2.0g of methyl vinyl ether-maleic anhydride copolymers, 2.0g of polyoxyethylene, 2.0g of carboxymethyl cellulose sodium, 12.0g of natural starch, 2.0g of menthol and 0.5g of doxycycline, and the rest is poval. The mouth mucosa drug sustained release preparation has the advantages that drug delivering is convenient, drug releasing time is long, drug releasing speed is even, targeting is strong, and adhesive force with mucosas is strong. In addition, the manufacturing method is simple in operation, low in cost, environment-friendly and suitable for industrial production.

The invention relates to a felodipine sustained-release tablet, wherein the percentages of raw and auxiliary materials of the sustained-release tablet in the total weight of the tablet core are: 1%-5%of felodipine, 30-80% of matrix material, 1-20% of filler, 1-10% of solubilizer, 10-30% of excipient, 1-10% of adhesive and 0.01-0.1% of antioxidant.